Abstract
Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status
Highlights
Based signaling potential and preferential expression by B lymphocytes[11]
Two separate fusions were performed and an extensive analysis of 92 FCRL2reactive hybridoma clones was undertaken. This screen led to the identification of 3E11, a mouse IgG1κ subclone that does not cross-react with the five other FCRL molecules expressed by human lymphocytes (Fig. S1)
Cells were analyzed by flow cytometry after co-staining with the following anti-FCRL2 monoclonal antibody (mAb) clones: directly with PE-conjugated 3E11 or indirectly with biotinylated 7F213 followed by streptavidin (SA)-PE (BD)
Summary
Based signaling potential and preferential expression by B lymphocytes[11]. In healthy donor peripheral blood mononuclear cell samples, the family member designated FCRL2 identifies subsets of CD19+CD27+ memory B cells and inhibits activation when co-ligated with the B-cell receptor, but has not been found to bind Ig12. Extended clinical follow-up of a previously characterized cohort of CLL patients (n = 107) assessed according to FCRL2 staining by flow cytometry using the 7F2 mAb as previously described[13]. The 3E11 anti-FCRL2 mAb was used to analyze samples from a new cohort of CLL patients (n = 99).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
